Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€3.62

€3.62

-0.820%
-0.03
-0.820%
€12.00
 
15:41 / Tradegate WKN: A2PKMZ / Symbol: NVAX / Name: Novavax / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Novavax Inc. Stock

The price for the Novavax Inc. stock decreased slightly today. Compared to yesterday there is a change of -€0.030 (-0.820%).
With 3 Buy predictions and 2 Sell predictions the community is currently undecided on Novavax Inc..
Based on the current price of 3.62 € the target price of 12 € shows a potential of 231.49% for Novavax Inc. which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Novavax Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Non-cyclic/Cyclic" there were negative voices in the community.

Pros and Cons of Novavax Inc. in the next few years

Pros
?
B****
?
S********** s********
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Novavax Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Novavax Inc. -0.820% -8.049% -24.665% -57.764% -18.253% -98.075% -61.253%
Ardelyx Inc. 0.100% -7.414% -16.973% 36.533% 6.298% -15.255% -
Salarius Pharmaceuticals Inc. 0.930% 6.468% -31.520% -69.209% -22.883% -98.226% -99.994%
Evolus Inc -2.630% -5.882% -12.500% 43.590% 19.786% 18.519% -

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-30

General Impression

The financials of Novavax, a Biotechnology & Medical Research company with US symbol NVAX, paint a mixed picture. Over the past few years, the company has reported a significant increase in its revenue and total assets. However, its net income has consistently been in the negative, and it has faced challenges in maintaining a positive net working capital and managing its liabilities.

Detailed Analysis

Comments

Novavax, Inc. (NASDAQ: NVAX) was upgraded by analysts at B. Riley from a "neutral" rating to a "buy" rating.
Ratings data for NVAX provided by MarketBeat
Show more

Novavax, Inc. (NASDAQ: NVAX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for NVAX provided by MarketBeat
Show more

Buy Novavax Inc.
Show more

News

Better Buy: Bluebird Bio Vs. Novavax: https://g.foolcdn.com/editorial/images/772574/physician-giving-a-high-five-to-a-young-patient.jpg
Better Buy: Bluebird Bio Vs. Novavax

If there is one thing Bluebird Bio (NASDAQ: BLUE) and Novavax (NASDAQ: NVAX) have in common, other than their belonging to the biotech industry, it is that both have seen their shares drop

Down 60% From Its 52-Week High, Is Novavax Stock a Buy?: https://g.foolcdn.com/editorial/images/772085/stock-traders-looking-at-a-chart.jpg
Down 60% From Its 52-Week High, Is Novavax Stock a Buy?

In just the past 12 months, Novavax (NASDAQ: NVAX) stock has plummeted 48% in value. The once-promising COVID vaccine maker has struggled mightily; it was late to getting a vaccine approved and to

1 Beaten-Down Stock to Buy and 1 to Avoid Like the Plague: https://g.foolcdn.com/editorial/images/771003/physician-on-a-virtual-consultation-with-patient.jpg
1 Beaten-Down Stock to Buy and 1 to Avoid Like the Plague

Sometimes it is worth it to buy shares of companies on the dip, and sometimes it isn't. It all depends on whether there are good reasons to believe the company in question will bounce back, and if